Cimpuciclib tosylate is a selective CDK4 inhibitor (IC50: 0.49 nM) that has anti-tumor activity[1].
Cimpuciclib (example 63, 141.2 nM, 6 days) tosylate inhibits proliferation of colo205 cells[1].
Cell Proliferation Assay[1]
| Cell Line: | Colo205 cells |
| Concentration: | 0-500 nM approximately |
| Incubation Time: | 6 days |
| Result: | Inhibited cell proliferation with an IC50 value of 141.2 nM. |
Cimpuciclib (example 63, 50 mg/kg, oral gavage, twice a week) tosylate inhibits tumor growth in colo205 tumor-bearing mice[1].
Cimpuciclib (5 mg/kg for rats, 50 mg/kg for colo205 tumor-bearing mice, oral administration) tosylate shows slow metabolic rate and maintains high concentration in the plasma[1].
| Animal Model: | Colo205 tumor-bearing mice[1] |
| Dosage: | 50 mg/kg, twice a week |
| Administration: | Oral gavage |
| Result: | Inhibited tumor growth by 93.63% |
| Animal Model: | Rats, colo205 tumor-bearing mice[1] | |||||||||||||||
| Dosage: | 5 mg/kg for rats, 50 mg/kg for colo205 tumor-bearing mice. | |||||||||||||||
| Administration: | Oral administration | |||||||||||||||
| Result: | Pharmacokinetic profile of Cimpuciclib (example 63).
|